Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells-Reference-Cited by-同舟云学术

Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells

Published:1997-07-01 Issue:2 Volume:32 Page:106-114
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Culig Zoran,Hobisch Alfred,Hittmair Anton,Cronauer Marcus V.,Radmayr Christian,Zhang Ju,Bartsch Georg,Klocker Helmut

Publisher

Wiley

Subject

Urology,Oncology

Reference47 articles.

1. : The prevention of LHRH induced disease flares in patients with metastatic carcinoma of the prostate. In (ed): “EORTC Genitourinary Group Monograph 8: Treatment Prostatic Cancer Facts and Controversies.” New York: Wiley-Liss, 125–129, 1990.

2. A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma

3. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones.

4. Agonists, but not antagonists, alter the conformation of the hormone-binding domain of androgen receptor.

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative transcriptomic analysis reveals reproductive impairments caused by PCBs and OH-PCBs through the dysregulation of ER and AR signaling;Science of The Total Environment;2022-01

2. CoMFA, CoMSIA, HQSAR and molecular docking analysis of ionone-based chalcone derivatives as antiprostate cancer activity;Indian Journal of Pharmaceutical Sciences;2016

3. Emerging biological observations in prostate cancer;Expert Review of Anticancer Therapy;2010-01

4. The Role of Cyclic AMP in Regulating the Androgen Receptor;Androgen Action in Prostate Cancer;2009

5. Intermittent Hormone Therapy in Nonmetastatic Prostate Cancer;Clinical Genitourinary Cancer;2006-09